Merit Medical price target lowered to $81 from $96 at Needham

Needham lowered the firm’s price target on Merit Medical to $81 from $96 and keeps a Buy rating on the shares. The company’s Q3 revenue and earnings beat expectations, with solid performance and strong free cash flow in the quarter, though organic revenue growth slowed to 7.1% in Q3 from 8.6% in Q2 as Merit Medical faced a more difficult comp, the analyst tells investors in a research note.